Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | HTR2C | P28335 | 6/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111685 | 0.85 | MTOR (0.49) | HTR2AHTR2CMTORBRAFMAPK14 | |
| SCHEMBL426838 | 0.84 | MTOR (0.56) | HTR2AHTR2CMTORBRAFMAPK14 | |
| SCHEMBL430172 | 0.84 | EPHX2 (0.57) | HTR2AHTR2CMTORBRAFMAPK14 | |
| SCHEMBL428867 | 0.84 | CYP3A4 (0.56) | MTOREPHX2 | |
| SCHEMBL3116358 | 0.84 | FLT3 (0.43) | JAK1HTR2AHTR2CMTORBRAF | |
| SCHEMBL3115513 | 0.83 | HSD17B10 (0.43) | HTR2AHTR2CMTORBRAFMAPK14 | |
| SCHEMBL3105854 | 0.83 | MAPT (0.44) | JAK1HTR2AHTR2CMTORBRAF | |
| SCHEMBL428259 | 0.82 | TSHR (0.52) | HTR2AHTR2CBRAFFLT3EPHX2 | |
| SCHEMBL3111433 | 0.82 | EPHX2 (0.48) | HTR2AHTR2CMTORFLT3EPHX2 | |
| SCHEMBL3115015 | 0.82 | EPHX2 (0.48) | HTR2AHTR2CMTOREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | claimed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | JAK1 150/4885PRKCQ 579/4885HTR2A 1871/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | JAK1 150/4885PRKCQ 579/4885HTR2A 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.